Apogee Therapeutics, Inc.
APGE
$39.94
$1.614.20%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 99.38% | 124.18% | 200.43% | 305.92% | 680.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.19% | 144.90% | 143.90% | 183.06% | 218.34% |
| Operating Income | -133.19% | -144.90% | -143.90% | -183.06% | -218.34% |
| Income Before Tax | -116.86% | -109.90% | -72.49% | -100.60% | -114.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -116.88% | -109.90% | -72.49% | -100.60% | -114.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.88% | -109.90% | -72.49% | -100.60% | -114.81% |
| EBIT | -133.19% | -144.90% | -143.90% | -183.06% | -218.34% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 56.00% | 72.74% | 87.42% | 66.68% | 47.71% |
| Normalized Basic EPS | 56.00% | 72.74% | 87.41% | 66.68% | 47.71% |
| EPS Diluted | 56.00% | 72.74% | 87.42% | 66.68% | 47.71% |
| Normalized Diluted EPS | 56.00% | 72.74% | 87.41% | 66.68% | 47.71% |
| Average Basic Shares Outstanding | 121.58% | 274.83% | 1,029.79% | 962.67% | 1,054.74% |
| Average Diluted Shares Outstanding | 121.58% | 274.83% | 1,029.79% | 962.67% | 1,054.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
